title: Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?
authors.affiliation: Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada. atul.chemi@gmail.com
authors.forename: Atul
authors.initials: A
authors.lastname: Bhardwaj
authors.forename: Jatinder
authors.initials: J
authors.lastname: Kaur
authors.forename: Edward E
authors.initials: EE
authors.lastname: Knaus
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001168:Arthritis / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000150:complications / Q000517:prevention & control; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D055808:Drug Discovery; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D020030:Nitric Oxide Donors / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D052246:Cyclooxygenase 2 Inhibitors; D007004:Hypoglycemic Agents; D020030:Nitric Oxide Donors